Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO.

Fiche publication

Date publication

mars 2026

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi , Mme HENRIQUES Julie

Tous les auteurs :
Boisteau E, Boilève A, Tougeron D, Vernerey D, De Malet A, Lecomte T, Aparicio T, Pernot S, Pinot J, Pellat A, Hautefeuille V, Farès N, Desgrippes R, Coriat R, Zaanan A, Edeline J, Philonenko S, Dubreuil O, Henriques J, Turpin A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41980356

Résumé

Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. In metastatic disease, evidence regarding the efficacy of chemotherapy (CT) combined with bevacizumab or anti-EGFR agents is limited to small studies. This study aimed to assess, in real-world practice, the effectiveness of first-line CT combined with targeted therapies (TT)-either antiangiogenic (AA) or anti-EGFR-compared with CT alone in patients with metastatic SBA (mSBA) and proficient mismatch repair/microsatellite stable (pMMR/MSS) status.